Program beneficiaries. The sample contains 5000 diabetes patients who were continuously eligible for Medicaid benefit and FAHS for at least 2 years. Medication adherence was measured with the Medication Possession Ratio (MPR) for diabetes-specific prescriptions, statins, and ACEs/ARBs. MPR was calculated separately for the first 12 months (baseline) and the following 12 months (follow-up). Costs were similarly summed over the 12 month intervals of baseline and follow-up. Estimation was performed with first-difference and conditional logistic regressions. RESULTS: Improvement in MPR between baseline and follow-up was reflected in lower inpatient, emergency room (ER), and total non-drug costs. A 10% improvement in MPR for hypoglycemic medications reduced inpatient costs by $127.97 (p = 0.002), ER costs by $3.72 (p = 0.003), and total non-drug costs by $116.00 (p = 0.009) over 12 months. This reduction in inpatient costs was the result of a shorter average length of stay: a decrease of 0.2 (p = 0.03) day per 10% increase in MPR. Finally, a 10% improvement in adherence with statins reduced the probability of being hospitalized by 4.3% (p = 0.01). CONCLUSION: This research demonstrates the existence of significant short-term savings related to the improvement of medication adherence among persons with diabetes.
Demand M, Gutierrez PR, Thiebaud P Pfizer Health Solutions, New York, NY, USA OBJECTIVE: The failure to maintain adherence to recommended medication and testing regimens is associated with excess morbidity and mortality among diabetics. This presentation focuses on the adherence patterns of diabetics enrolled in Florida: A Healthy State (FAHS), a Medicaid disease management program. METHODS: Attention is given to the baseline characteristics of program participants, and the association between them and baseline adherence to hypoglycemic agents, ACEI, ARB, Statins, and annual tests (HbA1C, lipids, microalbumin, retinal exam). A matched-group comparison examined changes in patterns of medication and test adherence at follow-up for those enrolled in the nurse care management module. RESULTS: A total of 8432 diabetic adults were continuously enrolled for 24 months. Multivariate models evaluating their baseline adherence to hypoglycemics, ACEI, ARB, Statins and recommended tests were fit. Those who were adherent to one class of diabetes-related medication were 1.5 to 3.5 times more likely to be adherent to another class of diabetes-related medication. Baseline adherence to recommended tests was associated with 50% greater odds of adherence to hypoglycemics, ACEI and Statin. The profile of the 2597 (31%) moderate and high risk participants that enrolled in the nurse care management module was significantly different than that of non-enrollees. Participants had more comorbidities, greater service utilization and costs, and lower medication and test adherence. In a matched-group comparison, nurse care management was associated with improved odds of: filling at least one script during the study period among those who were not using diabetes medications at baseline, adherence to insulin among those using diabetes medications at baseline, and adherence to recommended testing CONCLU-SION: A pattern of overall adherence behavior was observed at baseline. Participation in nurse care management improved adherence to recommended diabetes medication and testing regimens. It is believed that these results can be generalized to other Medicaid populations. The effect of insomnia along with the decreased cognitive functioning associated with aging is a serious concern within the elderly (65 years and older) population. We examined the association of patient health care utilization and depressive symtomatology with medication adherence in insomnia in Medicare-HMO enrolled elderly patients. METHODS: This was a retrospective, longitudinal cohort study which included elderly patients (65 and older) enrolled continuously for 1-5 years in the Medicare HMO. Medication possession ratio was used to estimate the adherence in insomnia medication. Different MPR thresholds (0.8, 0.6, 0.4 and 0.2) were used to determine non adherence. Associations between depressive symptoms, medication adherence and health care costs were assessed using ordinary least square multiple regressions. RESULTS: A total of 2068 patients with a primary diagnosis of insomnia were included in the study. Sixty percent of these patients had depressive symptomatology. The severity of comorbidity (Charlson index) was 4 and the patient perception of quality of life (Short Form-12 scores) were between 79 and 82. The prevalence of non adherence was 70% even with a low MPR of 0.2. Insomnia patients with depressive symptoms were 92% less likely to be adherent to their insomnia medications (p < 0.05). After controlling other variables, we found MPR was a good predictor of total health care costs (10% increases in MPR for every 2% decrease in total health care costs, p < 0.001). CONCLUSION: We found strong associations between depressive symtomatology, medication adherence, and health care costs in elderly patients with insomnia. Disease and risk management programs in managed care settings should be used to optimize the medication adherence in the elderly.
AC4 THE COST OF NON-ADHERENCE TO ASTHMA TREATMENT GUIDELINES AMONG A LOW-INCOME COHORT
Said Q 1 , Waitzman NJ 2 1 University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2 University of Utah, Salt Lake City, UT, USA OBJECTIVE: Investigate the effects of non-adherence by providers to the National Institutes of Health treatment guidelines on the costs of care for children and adults with asthma. The Guidelines recommend providing access to rescue medications but restricting their overuse through controller medications. METHODS: Pediatric (6-19 years) and adult (20-64 years) patients with a prescription for an albuterol inhaler (AI) or an inhaled corticosteroid (ICS) and a diagnosis for asthma between January 1, 2001 and December 31, 2005 were identified from the Utah Medicaid population. Patients were observed for ninety days following the first prescription and classified into three groups on the basis of AI use and ICS prescription, as following: 1) less than three canisters of AI (appropriate); 2) three or more canisters of AI (inappropriate); 3) no AI use but a prescription for ICS (inappropriate). Once categorized as adherent (group 1) or non-adherent (groups 2, 3), direct medical costs were estimated for children and adults for one year using generalized linear two-part regression models adjusting for demographics, comorbidities, smoking status, seasonal effects and year. RESULTS: Of the final sample (N = 4751), children comprised 40.4% (n = 1918; mean age 12.1 years; 51.2% male) and adults comprised 59.6% (n = 2833; mean age 39.2 years; 23.5% male). Only 69.3% children and 58.6% adults were in the adherent group (group 1). Compared with appropriate AI use, AI overuse was significantly associated with increased costs for both children ($3541 v. $7670; mean increase 117% [p = 0.001]) and adults ($3541 v. $5352; mean increase 21% [p = 0.009]). Similarly, compared with appropriate AI use, no AI use with ICS prescription was significantly associated with an increase in costs for both children and adults (mean increase 51.1% [p = 0.001] and 37.9% [p = 0.001], respectively). CONCLUSION: Lack of adherence with evidence-based treatment guidelines remains a significant problem. Interventions to improve guideline adherence have the potential to reduce costs. Clinical trials show the efficacy of combination beta-blocker (BB) and angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy for the treatment of chronic heart failure (CHF). We sought to test the effectiveness of these drugs in day-to-day health care.
CARDIOVASCULAR DISEASE OUTCOMES RESEARCH

METHODS:
The study was a retrospective analysis of a national cohort of patients diagnosed with CHF from October 1, 1996 through September 30, 2002 identified from the Department of Veterans Affairs electronic medical records system. Prevalent cases with CHF for at least 90 days as of October 1, 2001 (index date) were analyzed separately from incident cases identified after index date. Patients were classified into four treatment categories: BB, ACEI or ARB, Both and Neither according to their exposure after index date. Multiple logistic regression analysis was employed to assess the adjusted association between these treatments and mortality within 1 year after index date, controlling for demographic factors, years with CHF, 30 co-morbidities and co-medications. RESULTS: Prevalent cases: 231,109 patients were identified, with the crude death rate 8.8%. Majority of the cohort was male (98.2%) and age >65 years (76.1%). 28.3% of patients were on beta blockers only, 12.7% on ACEI or ARB only, 40.1% on both and 18.9% on neither. All three treatment options showed protective effect as compared to Neither. Adjusted OR (95% CI) were: BB 0.646 (0.616, 0.677), ACEI or ARB 0.708 (0.669, 0.749) and Both 0.460 (0.435, 0.488). The same pattern of protective effect remained for incident cases (N = 68,353). Adjusted OR (95% CI) were: BB 0.713 (0.652, 0.781), ACEI or ARB 0.780 (0.701, 0.868) and Both 0.614 (0.553, 0.681). CONCLUSION: Effectiveness of combination therapy of beta blockers and angiotensin inhibition was confirmed, supporting the use of evidence-based care to improve outcomes in the "real-world" setting.
